Continued on page 3
worldwide give rise to unique
Therapeutic drug monitoring (TDM) was not superior to standard treatment for patients tarting infliximab, in what is believed to be the first randomised, controlled trial studying its effectiveness in a range of immune-mediated inflammatory diseases, including rheumaticdiseases.
Silje Watterdal Syversen, PhD, a consultantrheumatologist and researcher at DiakonhjemmetHospital in Oslo, will speak about the trial – calledthe Norwegian Drug Monitoring trial part A(NOR-DRUM [A]) – during the Opening Plenary abstract session at the EULAR 2020 E-Congress onWednesday, 3 June.
“Better treatment strategies for TNF-alpha inhibitors [tumour necrosis factor–alpha; TNFi] are neededbecause many patients don’t achieve remission,”Dr. Syversen said. Adult patients with RA, psoriaticarthritis, spondyloarthritis, ulcerative colitis, Crohn’sdisease, and psoriasis were studied.
Dr. Syversen said that, even though some rheumatologists and many gastroenterologists alreadyuse proactive TDM in clinical practice, no clinicaltrial to date has shown that proactive TDM improves clinical outcomes in patients on TNFi. “Although TNFi are increasingly used, guidelines areinconsistent with their recommendations for usingTDM,” Dr. Syversen added.
Dr. Syversen and colleagues surmised thatTDM might be superior to standard treatment to
It is my sincere pleasure to wel- come you to the EULAR 2020 E-Congress. Two decades after the first annual congress, weare embarked upon a new andexciting course, albeit we wouldhave preferred to meet in person. Iam confident that you will find thee-congress to be a true celebration of scientific and educationalexcellence, offering updates at thecutting edge of the rheumatologyfield.
Our congress scientific committee, brilliantly lead by Prof. JohnIsaacs and Prof. Loreto Carmona,have reworked the programmeto provide a range of high-qualitypresentations, in mixed live andrecorded format. By this means,you will be able to enjoy the immediacy of the congress itself but inaddition will be offered time to reflect upon content for many weeksthereafter. We are also workingclosely together with our corporatemembers in enabling access tosatellite symposia. Taken together,I am confident that the learningthat we all so much appreciate inour annual meeting will be undiminished.
Clearly, the COVID-19 pandem-
ic has imposed unprecedented
changes in our personal and pro-
fessional lives. It was with great
disappointment that we cancelled
our congress planned in Frank-
furt. As international and political
events have evolved, it is clear that
this decision was correct. Much
energy and effort had already been
expended, not least by our rheuma-
tology colleagues in Germany, and
to them I extend my sincere thanks
for their unstinting commitment to
EULAR and gracious acceptance
of recent events. Thanks are due
also to our corporate members for
their understanding of the altered
circumstances of this congress and
for their flexibility in this matter.
Continued on page 3